A Phase 2 interventional study of nal-IRI and 5 fluorouracil in Pancreatic Cancer, sponsored by Ipsen. Completed at 36 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-10.
Sponsored by Ipsen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms — 10 open to participants now, 12 under way, none of them phase 3. irinotecan sucrosofate · Pancreatic Neoplasms.
Among the 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms, this one is the 14th largest by enrollment, is the only one that started in 2015, is one of 13 in phase 2, and was the 4th registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,002 are open to participants now.
Browse Pancreatic Neoplasms studies →10 of the 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
SONIRE Therapeutics Inc. · Sites in United States
Ages 18+
Kuirong Jiang · Sites in China
Ages 18–75
Du Juan · Sites in China
Ages 18+
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18–75
National Taiwan University Hospital · Sites in Taiwan
Ages 20–75
By country, each count listing its studies:
irinotecan sucrosofate: first FDA approval 2015 (ONIVYDE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 742 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 15 · Phase 3 2
First in 2009; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 64 across the 23 interventional studies. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 23 have an industry lead sponsor. The 10 most frequent:
Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
Ipsen has 2 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing irinotecan sucrosofate in Pancreatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07033689SONIRE Therapeutics Inc.Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II) | 2026-12-01 |
| NCT06494514Du JuanNALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer | 2027-04-01 |
| NCT06513455Harbin Medical UniversityIrinotecan Liposome,Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing irinotecan sucrosofate in Pancreatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, phase 2 non-comparative study to assess the safety, tolerability, and preliminary efficacy of nal-IRI in combination with other anticancer therapies in patients not previously treated for metastatic pancreatic adenocarcinoma. This study will assess the following regimen:
The study will be conducted in two parts:
Part 1, consisting of an initial dose exploration (Part 1A) followed by dose expansion (Part 1B) of the irinotecan liposome injection +5-FU/LV + oxaliplatin regimen and Part 2, consisting of a comparison of irinotecan liposome injection-containing regimen versus nab-paclitaxel plus gemcitabine. The comparative Part 2 was removed in a protocol amendment, dated 11 April 2018 (Version 6.0), before it was initiated, as this comparative part of the study is being undertaken as a stand-alone phase III study D-US-60010-001. This CSR only pertains to the single-arm dose exploration and dose expansion Part 1 results and no further reference is made to the comparative Part 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: nal-IRI · Drug: 5 fluorouracil · Drug: Leucovorin · Drug: Oxaliplatin
Also known as: MM-398
Also known as: 5-FU
Also known as: LV
Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT)
Adverse events (AEs) were considered to be DLTs if they occurred during the safety evaluation period (i.e, 28 days of Cycle 1; or 14 days after the second dose of study treatment if there was a treatment delay) and were deemed related to the study treatment regimen. Any AE that was related to disease progression was not considered a DLT.
Time frame: From the start of the first study treatment (Cycle 1 Day 1) up to 14 days after the second dose of study treatment, maximum of 42 days
Median Progression Free Survival (PFS)
The PFS was defined as the time from date of first study treatment to the first documented radiographical progression of disease (PD), per investigator using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, or death from any cause, whichever comes first. The PFS was calculated using Kaplan-Meier technique.
Time frame: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, end of treatment (EoT) visit, then every 2 months thereafter (maximum of 278 weeks).
Best Overall Response (BOR)
The BOR was defined as the best response (complete response \[CR\] + partial response \[PR\] + stable disease \[SD\]) recorded from the start of study treatment until disease progression or start of new anticancer therapy using RECIST Version 1.1.
Time frame: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).
Overall Response Rate (ORR)
The ORR was defined as the percentage of participants with a BOR characterized as either a CR or PR relative to the total number of evaluable participants using RECIST Version 1.1. Evaluable participants were defined as treated participants with measurable disease at baseline.
Time frame: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).
Disease Control Rate (DCR)
The DCR was defined as percentage of participants with CR or PR or SD or Non-PD/Non-CR, per RECIST Version 1.1 relative to total number of treated participants with measurable disease at baseline.
Time frame: At Week 16
Median Overall Survival (OS)
The OS was the time from date of first study treatment to the date of death from any cause. Participant survival data were collected from all available sources. The OS was calculated using Kaplan-Meier technique.
Time frame: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).
Median Duration of Response (DoR)
The DoR was defined as the time from the first date of response (CR or PR) to first date of documented radiographical PD, per investigator using RECIST Version 1.1. This only applied to participants with CR or PR. If a participant was given a new anticancer therapy prior to first response, DoR was not calculated. The DoR was calculated using Kaplan-Meier technique.
Time frame: RECIST assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, EoT visit, then every 2 months thereafter (maximum of 278 weeks).
This Phase 2 non-comparative, open-label study was conducted in previously untreated metastatic pancreatic cancer participants at 15 investigational sites in Australia, Spain and USA between 19 October 2015 and 15 February 2021.
| Milestone | Dose Exploration: Cohort 1 | Dose Exploration: Cohort -1 | Dose Exploration: Cohort -2B | Dose Exploration: Cohort -3 | Dose Expansion: Cohort -1 |
|---|---|---|---|---|---|
| Started | 7 | 7 | 10 | 7 | 25 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 7 | 10 | 7 | 25 |
| Withdrew: Death | 5 | 7 | 8 | 7 | 17 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Sponsor decision | 1 | 0 | 1 | 0 | 5 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 |
Adverse events (AEs) were considered to be DLTs if they occurred during the safety evaluation period (i.e, 28 days of Cycle 1; or 14 days after the second dose of study treatment if there was a treatment delay) and were deemed related to the study treatment regimen. Any AE that was related to disease progression was not considered a DLT.
| Participants | Dose Exploration: Cohort 1 | Dose Exploration: Cohort -1 | Dose Exploration: Cohort -2B | Dose Exploration: Cohort -3 |
|---|---|---|---|---|
| Part 1A: Number of Participants With Dose-Limiting Toxicities (DLT) | 2 | 1 | 2 | 0 |
The PFS was defined as the time from date of first study treatment to the first documented radiographical progression of disease (PD), per investigator using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, or death from any cause, whichever comes first. The PFS was calculated using Kaplan-Meier technique.
| months | Dose Exploration: Cohort 1 | Dose Exploration: Cohort -1 | Dose Exploration: Cohort -2B | Dose Exploration: Cohort -3 | Dose Expansion: Cohort -1 | Cohort -1: Pooled |
|---|---|---|---|---|---|---|
| Median Progression Free Survival (PFS) | 9.7 (2.96 to NA) | 32.3 (0.53 to NA) | 9.2 (0.46 to NA) | 3.8 (1.22 to 5.78) | 9.2 (7.59 to 11.20) | 9.2 (7.59 to 11.96) |
The BOR was defined as the best response (complete response \[CR\] + partial response \[PR\] + stable disease \[SD\]) recorded from the start of study treatment until disease progression or start of new anticancer therapy using RECIST Version 1.1.
| Participants | Dose Exploration: Cohort 1 | Dose Exploration: Cohort -1 | Dose Exploration: Cohort -2B | Dose Exploration: Cohort -3 | Dose Expansion: Cohort -1 | Cohort -1: Pooled |
|---|---|---|---|---|---|---|
| Best Overall Response (BOR) | 2 | 6 | 4 | 4 | 20 | 26 |
The ORR was defined as the percentage of participants with a BOR characterized as either a CR or PR relative to the total number of evaluable participants using RECIST Version 1.1. Evaluable participants were defined as treated participants with measurable disease at baseline.
| percentage of participants | Dose Exploration: Cohort 1 | Dose Exploration: Cohort -1 | Dose Exploration: Cohort -2B | Dose Exploration: Cohort -3 | Dose Expansion: Cohort -1 | Cohort -1: Pooled |
|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) | 0 (0 to 41.0) | 42.9 (9.9 to 81.6) | 30.0 (6.7 to 65.2) | 14.3 (0.4 to 57.9) | 32.0 (14.9 to 53.5) | 34.4 (18.6 to 53.2) |
The DCR was defined as percentage of participants with CR or PR or SD or Non-PD/Non-CR, per RECIST Version 1.1 relative to total number of treated participants with measurable disease at baseline.
| percentage of participants | Dose Exploration: Cohort 1 | Dose Exploration: Cohort -1 | Dose Exploration: Cohort -2B | Dose Exploration: Cohort -3 | Dose Expansion: Cohort -1 | Cohort -1: Pooled |
|---|---|---|---|---|---|---|
| Disease Control Rate (DCR) | 42.9 (9.9 to 81.6) | 71.4 (29.0 to 96.3) | 40.0 (12.2 to 73.8) | 28.6 (3.7 to 71.0) | 72.0 (50.6 to 87.9) | 71.9 (53.3 to 86.3) |
The OS was the time from date of first study treatment to the date of death from any cause. Participant survival data were collected from all available sources. The OS was calculated using Kaplan-Meier technique.
| months | Dose Exploration: Cohort 1 | Dose Exploration: Cohort -1 | Dose Exploration: Cohort -2B | Dose Exploration: Cohort -3 | Dose Expansion: Cohort -1 | Cohort -1: Pooled |
|---|---|---|---|---|---|---|
| Median Overall Survival (OS) | 12.6 (3.98 to 21.03) | 12.5 (0.53 to 12.71) | 16.6 (0.69 to 26.74) | 5.8 (1.35 to 14.65) | 12.7 (8.18 to 23.66) | 12.6 (8.74 to 19.12) |
The DoR was defined as the time from the first date of response (CR or PR) to first date of documented radiographical PD, per investigator using RECIST Version 1.1. This only applied to participants with CR or PR. If a participant was given a new anticancer therapy prior to first response, DoR was not calculated. The DoR was calculated using Kaplan-Meier technique.
| months | Dose Exploration: Cohort 1 | Dose Exploration: Cohort -1 | Dose Exploration: Cohort -2B | Dose Exploration: Cohort -3 | Dose Expansion: Cohort -1 | Cohort -1: Pooled |
|---|---|---|---|---|---|---|
| Median Duration of Response (DoR) | — | 28.4 (3.52 to NA) | NA (NA to 16.39) | — | 9.4 (2.20 to NA) | 9.4 (3.52 to NA) |
Collected over Treatment-emergent adverse events are reported from the time of first study treatment administration (Day 1) up to 30 days after the date of last study treatment administration or until the start of alternative anticancer therapy, approximately 1008 days. All-Cause Mortality are reported from first participant enrolled to last participant died, approximately 1946 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Exploration: Cohort 1 | 5/7 (71.4%) | 6/7 (85.7%) | 7/7 (100%) |
| Dose Exploration: Cohort -1 | 7/7 (100%) | 2/7 (28.6%) | 7/7 (100%) |
| Dose Exploration: Cohort -2B | 8/10 (80%) | 7/10 (70%) | 10/10 (100%) |
| Dose Exploration: Cohort -3 | 7/7 (100%) | 4/7 (57.1%) | 7/7 (100%) |
| Dose Expansion: Cohort -1 | 17/25 (68%) | 15/25 (60%) | 25/25 (100%) |
| Event | Dose Exploration: Cohort 1 | Dose Exploration: Cohort -1 | Dose Exploration: Cohort -2B | Dose Exploration: Cohort -3 | Dose Expansion: Cohort -1 |
|---|---|---|---|---|---|
| Abdominal PainGastrointestinal disorders | 0/7 | 0/7 | 0/10 | 3/7 | 1/25 |
| DiarrhoeaGastrointestinal disorders | 2/7 | 1/7 | 1/10 | 1/7 | 1/25 |
| ColitisGastrointestinal disorders | 0/7 | 0/7 | 0/10 | 2/7 | 1/25 |
| VomitingGastrointestinal disorders | 1/7 | 0/7 | 2/10 | 0/7 | 3/25 |
| Small Intestinal ObstructionGastrointestinal disorders | 0/7 | 0/7 | 0/10 | 1/7 | 1/25 |
| EnteritisGastrointestinal disorders | 1/7 | 0/7 | 0/10 | 0/7 | 0/25 |
| Large Intestinal ObstructionGastrointestinal disorders | 1/7 | 0/7 | 0/10 | 0/7 | 0/25 |
| Upper Gastrointestinal HaemorrhageGastrointestinal disorders | 0/7 | 1/7 | 0/10 | 0/7 | 0/25 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/7 | 1/7 | 0/10 | 0/7 | 2/25 |
| Anaemia of Malignant DiseaseBlood and lymphatic system disorders | 0/7 | 0/7 | 0/10 | 1/7 | 0/25 |
| Event | Dose Exploration: Cohort 1 | Dose Exploration: Cohort -1 | Dose Exploration: Cohort -2B | Dose Exploration: Cohort -3 | Dose Expansion: Cohort -1 |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 5/7 | 6/7 | 9/10 | 5/7 | 23/25 |
| DiarrhoeaGastrointestinal disorders | 6/7 | 5/7 | 6/10 | 6/7 | 22/25 |
| Decreased appetiteMetabolism and nutrition disorders | 5/7 | 6/7 | 4/10 | 3/7 | 12/25 |
| VomitingGastrointestinal disorders | 5/7 | 4/7 | 5/10 | 3/7 | 14/25 |
| FatigueGeneral disorders | 5/7 | 5/7 | 7/10 | 5/7 | 16/25 |
| DepressionPsychiatric disorders | 1/7 | 5/7 | 1/10 | 1/7 | 2/25 |
| ConstipationGastrointestinal disorders | 3/7 | 4/7 | 4/10 | 1/7 | 13/25 |
| Abdominal painGastrointestinal disorders | 2/7 | 3/7 | 3/10 | 4/7 | 8/25 |
| FlatulenceGastrointestinal disorders | 0/7 | 4/7 | 2/10 | 1/7 | 1/25 |
| HypokalaemiaMetabolism and nutrition disorders | 4/7 | 2/7 | 5/10 | 3/7 | 12/25 |
Safety population included participants who received at least 1 dose of any study treatment.
| Age, Customized(Participants) | Dose Exploration: Cohort 1 | Dose Exploration: Cohort -1 | Dose Exploration: Cohort -2B | Dose Exploration: Cohort -3 | Dose Expansion: Cohort -1 | Total |
|---|---|---|---|---|---|---|
| < 65 years | 4 | 4 | 3 | 4 | 19 | 34 |
| >= 65 years | 3 | 3 | 7 | 3 | 6 | 22 |
| Sex: Female, Male(Participants) | Dose Exploration: Cohort 1 | Dose Exploration: Cohort -1 | Dose Exploration: Cohort -2B | Dose Exploration: Cohort -3 | Dose Expansion: Cohort -1 | Total |
|---|---|---|---|---|---|---|
| Female | 6 | 4 | 2 | 2 | 14 | 28 |
| Male | 1 | 3 | 8 | 5 | 11 | 28 |
| Race/Ethnicity, Customized(Participants) | Dose Exploration: Cohort 1 | Dose Exploration: Cohort -1 | Dose Exploration: Cohort -2B | Dose Exploration: Cohort -3 | Dose Expansion: Cohort -1 | Total |
|---|---|---|---|---|---|---|
| White | 6 | 7 | 9 | 7 | 21 | 50 |
| Black or African American | 0 | 0 | 0 | 0 | 2 | 2 |
| Asian | 1 | 0 | 1 | 0 | 1 | 3 |
| Not Reportable | 0 | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Dose Exploration: Cohort 1 | Dose Exploration: Cohort -1 | Dose Exploration: Cohort -2B | Dose Exploration: Cohort -3 | Dose Expansion: Cohort -1 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 4 | 4 |
| Not Hispanic or Latino | 7 | 7 | 10 | 7 | 21 | 52 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in Feb 2021, 63 months.
Results were first posted in Oct 2022, 1 year 7 months after primary completion.
Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 63 months is above that.
Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Irinotecan sucrosofate